Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

by B2i | Apr 26, 2023 | Press Releases

JUPITER, Fla., April 26, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

by B2i | Apr 18, 2023 | Press Releases

JUPITER, Fla., April 18, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent

by B2i | Apr 12, 2023 | Press Releases

JUPITER, Fla., April 12, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

Dyadic to Present at World Vaccine Congress Washington 2023

by B2i | Mar 30, 2023 | Press Releases

JUPITER, Fla., March 30, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Reports 2022 Year End Results and Recent Company Progress

by B2i | Mar 29, 2023 | Press Releases

Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all...